-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although the SARS-CoV-2 vaccine is very safe, two reports were recently published in Annals of Neurology, each reporting Guillain-Barre syndrome after vaccination with the new crown vaccine
Christopher Martin Allen reported 4 cases of bilateral weakness of the Guillain-Barré syndrome (GBS) paresthesia variant that occurred within 3 weeks of the Oxford-AstraZeneca SARS-CoV-2 vaccine
Infect
Guillain-Barré syndrome (GBS) is an acute uniphasic immune- mediated polyneurotic neuropathy, usually manifested as a first infectious disease
immunity
Christopher Martin Allen et al.
All patients showed severe bilateral weakness (facial diplegia) and normal facial sensation
Blood vessel
Christopher Martin Allen's GBS patients usually have a median time of onset of 11 days, and symptoms appear 11 to 22 days after vaccination, which coincides with the period when the maximum immune response to the vaccine is expected
The median time to onset of
The incidence of GBS after vaccination is unlikely to increase The incidence of GBS after vaccination is unlikely to increase FDA GBS incidence increased by 1.
Diagnosis of neurological syndrome after vaccination may be due to the production of host antibodies, which cross-react with proteins present in the peripheral myelin sheath
thrombus
In short, after the SARS-CoV-2 vaccine, one should be alert to the occurrence of facial weakness and paresthesia variant GBS, and it is recommended that the post-vaccination monitoring program ensure reliable data collection for this result to assess causality
After the SARS-CoV-2 vaccine is administered, one should be alert to the occurrence of facial weakness and paresthesia variant GBS, and it is recommended that the post-vaccination monitoring program ensure reliable data collection of this result to assess causality
Original source
1.
1.
2.
Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination
in this message